COPD und Begleiterkrankungen Ergebnisse des Expertentreffens Luftschlösser 2008 Tremsbüttel, 28.–29. November 2008 Sponsor: Boehringer Ingelheim Pharma GmbH&Co KG

„Outcomes we did not anticipate“ –Mit dieser Bewertung fassten Calverley und Rennard 2007 die unerwarteten Resultate umfangreicher neuerer Studien zur COPD zusammen [1]. Zu diesen unerwarteten Resultaten gehörten nicht nur die begrenzte Nützlichkeit von Reversibilitätstests, die Häufigkeit von Pneumonien unter inhalativen Glukokortikosteroiden und die Erkenntnis, dass Studienteilnehmer nicht unbedingt repräsentativ für das Krankheitsbild der COPD sind. Patienten mit erheblichen Komorbiditäten, wie der koronaren Herzkrankheit, der Linksherzinsuffizienz oder Krebsleiden, werden meistens aus klinischen COPD-Studien ausgeschlossen. Diese Erkrankungen sind bei COPD jedoch für die Prognose mitentscheidend [2]. Auch in Studien, in denen Komorbiditäten nicht ausgeschlossen wurden, weil bei diesen keine rasche Mortalität angenommen wurde [3,4], verstarben mehr als 25% der Studienteilnehmer an kardiovaskulären Ursachen und 20% an Tumoren, davon die Hälfte an Lungenkrebs. Obwohl die gemeinsame Noxe, das Zigarettenrauchen, eine naheliegende Erklärung dieser Assoziationen ist, stellt die COPD offenbar ein zusätzliches Risiko dar. Für zukünftige COPD-Studien ist daher der Parameter „Tod durch alle Ursachen“ (all-cause mortality) als primärer Endpunkt besonders geeignet. Die COPD muss in Studien als Erkrankung mit gewichtigen Komorbiditäten betrachtet werden, die für den Verlauf und die Prognose mitentscheidend sind. Es ist die besonders bedeutsame Erkenntnis der Datenlage, dass Studien ohne den Einschluss von Patienten mit Komorbiditäten als Studien bei nicht-repräsentativen Subgruppen zu bewerten sind. Das Thema COPD und Begleiterkrankungen wurde daher von einer Expertengruppe am 28. und 29.11.2008 erörtert, mit dem Ziel, die Bedeutung der komplexen gesundheitlichen Situation von Patientenmit COPD zu analysieren. Dieser Beitrag stellt die Zusammenfassung der wesentlichen Ergebnisse dar.

[1]  M. Padeletti,et al.  Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. , 2007, Journal of the American College of Cardiology.

[2]  R. Abbott,et al.  Association of snoring with chronic bronchitis. , 2008, Archives of internal medicine.

[3]  S. Sidney,et al.  COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. , 2005, Chest.

[4]  J. Barberà,et al.  Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[5]  D. Sin,et al.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[6]  E. Wouters,et al.  Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[7]  G. Donaldson,et al.  Inflammatory changes, recovery and recurrence at COPD exacerbation , 2007, European Respiratory Journal.

[8]  L. Fabbri,et al.  Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.

[9]  T. Pietras,et al.  Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. , 1999, Respiratory medicine.

[10]  G. Rohde,et al.  Inflammatory Response in Acute Viral Exacerbations of COPD , 2008, Infection.

[11]  E. Salpeter,et al.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.

[12]  P. Barnes,et al.  Exhaled biomarkers. , 2006, Chest.

[13]  H. Worth,et al.  COPD und Psyche - ein Überblick , 2005 .

[14]  W. Maziak,et al.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[15]  P. Gibson,et al.  Eosinophilic bronchitis: clinical manifestations and implications for treatment , 2002, Thorax.

[16]  R. Stockley,et al.  Rate of progression of lung function impairment in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[17]  S. Sethi Infectious etiology of acute exacerbations of chronic bronchitis. , 2000, Chest.

[18]  T. Gislason,et al.  Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity , 2006, Respiratory research.

[19]  B E Ainsworth,et al.  Compendium of physical activities: an update of activity codes and MET intensities. , 2000, Medicine and science in sports and exercise.

[20]  Marta Benet,et al.  Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. , 2007, American journal of respiratory and critical care medicine.

[21]  Ciro Casanova,et al.  Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. , 2008, Chest.

[22]  K. Kostikas,et al.  VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. , 2009, Lung cancer.

[23]  A. Vgontzas Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? , 2008, Archives of physiology and biochemistry.

[24]  J. Vestbo,et al.  Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[25]  R. Cook,et al.  Changing pattern of sputum cell counts during successive exacerbations of airway disease. , 2007, Respiratory medicine.

[26]  F. Maltais,et al.  Aerobic and strength training in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[27]  H. Magnussen,et al.  In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. , 2001, Respiratory medicine.

[28]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[29]  P. Jones,et al.  Outcomes and markers in the assessment of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[30]  K. Davis,et al.  Trends and Cardiovascular Co-morbidities of COPD Patients in the Veterans Administration Medical System, 1991–1999 , 2005, COPD.

[31]  M. Etminan,et al.  Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.

[32]  F. Rutten,et al.  Comparison of B‐type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease , 2007, European journal of heart failure.

[33]  P. Jones,et al.  Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease , 2006, Thorax.

[34]  R. Henry,et al.  Reduced mechanical efficiency in chronic obstructive pulmonary disease but normal peak VO2 with small muscle mass exercise. , 2004, American journal of respiratory and critical care medicine.

[35]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[36]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[37]  R. Sakalauskas,et al.  Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. , 2007, Respiratory medicine.

[38]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[39]  P. Paré,et al.  Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. , 2007, American journal of respiratory and critical care medicine.

[40]  P. Barnes,et al.  Clinical aspects of exhaled nitric oxide. , 2000, The European respiratory journal.

[41]  D. Sin,et al.  Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[42]  N. Snell,et al.  The clinical utility of biomarkers in asthma and COPD. , 2008, Current opinion in pharmacology.

[43]  R. Rogers,et al.  Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. , 1989, The American review of respiratory disease.

[44]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[45]  S. Quintana,et al.  Mortality after hospitalization for COPD. , 2002, Chest.

[46]  Fernando Holguin,et al.  Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. , 2005, Chest.

[47]  Robert Wise,et al.  Predictors of mortality in patients with emphysema and severe airflow obstruction. , 2006, American journal of respiratory and critical care medicine.

[48]  P. Hirth,et al.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.

[49]  Emiel F M Wouters,et al.  Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. , 2007, Proceedings of the American Thoracic Society.

[50]  B. Celli,et al.  Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[51]  B. Celli,et al.  The 6‐min walk distance: change over time and value as a predictor of survival in severe COPD , 2004, European Respiratory Journal.

[52]  W. Bailey,et al.  Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. , 2008, Thorax.

[53]  C. Pichard,et al.  Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. , 1997, American journal of respiratory and critical care medicine.

[54]  K. Schmid,et al.  Bronchoalveoläre Lavage , 2007, Der Pathologe.

[55]  B. Celli,et al.  Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. , 2007, Chest.

[56]  M. Knuiman,et al.  Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. , 2004, Diabetes care.

[57]  V. Tirlapur Nocturnal deaths among patients with chronic bronchitis and emphysema. , 1984, British medical journal.

[58]  X. Busquets,et al.  Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[59]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[60]  R. Jörres Modelling the production of nitric oxide within the human airways. , 2000, The European respiratory journal.

[61]  P. Schnohr,et al.  Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study , 2006, Thorax.

[62]  P. Barnes,et al.  Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. , 2003, Chest.

[63]  Urs Frey,et al.  Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control , 2008, The Lancet.

[64]  J. Vestbo,et al.  COPD-related morbidity and mortality after smoking cessation: status of the evidence , 2008, European Respiratory Journal.

[65]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[66]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[67]  E. Wouters,et al.  Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. , 2000, Clinics in chest medicine.

[68]  D. Postma,et al.  Increased systemic inflammation is a risk factor for COPD exacerbations. , 2008, Chest.

[69]  Shing M. Lee,et al.  Hemodynamic characterization of patients with severe emphysema. , 2002, American journal of respiratory and critical care medicine.

[70]  G. Washko,et al.  The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[71]  H. Krumholz,et al.  Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. , 2001, Journal of the American College of Cardiology.

[72]  J. Soriano,et al.  C-reactive protein in patients with COPD, control smokers and non-smokers , 2005, Thorax.

[73]  B. M. Lewis,et al.  THE NATURAL HISTORY OF EMPHYSEMA. , 1964, Geriatrics.

[74]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[75]  Samia Mora,et al.  Physical Activity and Reduced Risk of Cardiovascular Events: Potential Mediating Mechanisms , 2007, Circulation.

[76]  K. P. Van de Woestijne,et al.  Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. , 1967, The American review of respiratory disease.

[77]  B. Gersh,et al.  Time to Presentation With Acute Myocardial Infarction in the Elderly: Associations With Race, Sex, and Socioeconomic Characteristics , 2000, Circulation.

[78]  K. Lam,et al.  Obstructive sleep apnea is independently associated with insulin resistance. , 2002, American journal of respiratory and critical care medicine.

[79]  S. Jann,et al.  Peripheral neuropathy in chronic respiratory insufficiency. , 1998, Journal of the peripheral nervous system : JPNS.

[80]  D. Sin,et al.  Systemic inflammation and mortality in chronic obstructive pulmonary disease. , 2007, Canadian journal of physiology and pharmacology.

[81]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[82]  A. Pickard,et al.  Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease , 2008, Annals of Internal Medicine.

[83]  K. Tatara,et al.  Cigarette Smoking and Risk for Impaired Fasting Glucose and Type 2 Diabetes in Middle-Aged Japanese Men , 2000, Annals of Internal Medicine.

[84]  B. Celli,et al.  The modified BODE index: validation with mortality in COPD , 2008, European Respiratory Journal.

[85]  J. Wedzicha,et al.  Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[86]  I. Pavord,et al.  Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. , 2006, American journal of respiratory and critical care medicine.

[87]  H. Magnussen,et al.  Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. , 2009, ATS 2009.

[88]  B. Celli,et al.  Exacerbations of chronic obstructive pulmonary disease , 2007, European Respiratory Journal.

[89]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[90]  E. Wouters,et al.  Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. , 1995, American journal of respiratory and critical care medicine.

[91]  S. Redline,et al.  Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. , 2004, American journal of epidemiology.

[92]  F. Maltais,et al.  Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[93]  P. Ponikowski,et al.  ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. , 2006, Clinical nutrition.

[94]  Thierry Troosters,et al.  Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[95]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[96]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[97]  E. Wouters,et al.  Chronic obstructive pulmonary disease • 5: Systemic effects of COPD , 2002, Thorax.

[98]  C. Özge,et al.  Cranial optic nerve involvements in patients with severe COPD , 2005, Respirology.

[99]  C. Y. Wang,et al.  NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.

[100]  A. Dirksen,et al.  Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[101]  G. Folkerts,et al.  Cells, mediators and Toll-like receptors in COPD. , 2008, European journal of pharmacology.

[102]  F. Blasi,et al.  Anxiety and depression in COPD patients: The roles of gender and disease severity. , 2006, Respiratory medicine.

[103]  S. Rennard,et al.  What have we learned from large drug treatment trials in COPD? , 2007, The Lancet.

[104]  F. Maltais,et al.  Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease , 2008, Chronic respiratory disease.

[105]  P. Barnes,et al.  Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD , 2002, Thorax.

[106]  J. Liao,et al.  Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.

[107]  D. Blumenthal,et al.  Mortality Rate in Veterans with Multiple Chronic Conditions , 2007, Journal of General Internal Medicine.

[108]  C. Furberg,et al.  Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[109]  D A Lynch,et al.  Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. , 2001, American journal of respiratory and critical care medicine.

[110]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[111]  H. Magnussen,et al.  Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. , 2008, American journal of respiratory and critical care medicine.

[112]  H. Coxson,et al.  Antielastin autoimmunity in tobacco smoking–induced emphysema , 2007, Nature Medicine.

[113]  S. Zakynthinos,et al.  Effects of rehabilitative exercise on peripheral muscle TNF&agr;, IL-6, IGF-I and MyoD expression in patients with COPD , 2007, Thorax.

[114]  Y. Lacasse,et al.  Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[115]  F. Hargreave,et al.  Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. , 1998, American journal of respiratory and critical care medicine.